Amanote Research
Register
Sign In
Patient-Reported Outcome Claims in European and United States Orphan Drug Approvals
Value in Health
- United Kingdom
doi 10.1016/j.jval.2018.07.836
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
September 1, 2018
Authors
S Jarosławski
M Toumi
P Auquier
C Dussart
Publisher
Elsevier BV
Related search
Analysis of Orphan Drug Designations and Approvals in the United States and the European Union
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Prm74 - Clinical Outcome Assessments in Drug Approvals: A Review of Label Claims in the United States and Europe (2013-2017)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Orphan Drug Approvals in Europe: Historical Review and Trends
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
FDA Reported Use of Patient Experience Data in 2018 Drug Approvals
Therapeutic Innovation and Regulatory Science
Pharmacology
Public Health
Environmental
Toxicology
Pharmaceutics
Occupational Health
Patient-Reported Outcomes in Orphan Drug Labels Approved by the US FDA
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Quantifying the Persisting Orphan-Drug Shortage Public Health Crisis in the United States
Journal of Market Access & Health Policy
Patient-Reported Outcome Measurement
Journal of the Royal Society of Medicine
Medicine
Drug Use and Sexual Behaviors Reported by Adults: United States, 1999-2002
The Iran-United States Claims Tribunal
